Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.31% | -48.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.31% | -48.32% | |||
| Cost of Revenue | -16.64% | -73.80% | |||
| Gross Profit | -12.91% | -41.35% | |||
| SG&A Expenses | -16.75% | -12.02% | |||
| Depreciation & Amortization | 0.01% | -0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.30% | -35.42% | |||
| Operating Income | -13.33% | -62.96% | |||
| Income Before Tax | -142.72% | -59.77% | |||
| Income Tax Expenses | -190.98% | -49.73% | |||
| Earnings from Continuing Operations | -129.80% | -61.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -129.80% | -61.81% | |||
| EBIT | -13.33% | -62.96% | |||
| EBITDA | -9.45% | -55.33% | |||
| EPS Basic | -129.56% | -62.10% | |||
| Normalized Basic EPS | -82.08% | 101.77% | |||
| EPS Diluted | -131.72% | -62.74% | |||
| Normalized Diluted EPS | -80.79% | 98.41% | |||
| Average Basic Shares Outstanding | 0.80% | 0.76% | |||
| Average Diluted Shares Outstanding | -5.94% | 2.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||